Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Relapsing-remitting multiple Sclerosis
75%
Multiple Sclerosis
57%
Low Intensity
50%
Stem Cell Therapy
50%
Autologous Hematopoietic Stem Cell
50%
Antithymocyte Globulin
39%
Cyclophosphamide
32%
High Disease Activity
25%
Efficacy Index
25%
Conditioning Regimen
25%
Young Patients
25%
Denmark
25%
Chemotherapy
25%
Immunosuppression
25%
Safety Profile
25%
Long-term Treatment
25%
Cytarabine Arabinoside
7%
No Evidence of Disease
7%
Event-free Survival
7%
Carmustine
7%
Severe Adverse Events
7%
Relapse-free Survival
7%
Patient Characteristics
7%
Safe Treatment
7%
Etoposide
7%
Treatment-related Mortality
7%
Effective Treatment
7%
Single Center
7%
NEDA-3
7%
Melphalan
7%
Treatment Options
7%
Free Survival
7%
Single-center Study
7%
Serious Adverse Events
7%
Medicine and Dentistry
Autologous Hematopoietic Stem Cell Transplantation
100%
Multiple Sclerosis
100%
Hematopoietic Stem Cell
50%
Thymocyte Antibody
39%
Cyclophosphamide
32%
Immunosuppressive Treatment
25%
Conditioning
25%
Disease Activity
25%
Adverse Event
14%
Etoposide
7%
Event Free Survival
7%
Recurrence Free Survival
7%
Carmustine
7%
Melphalan
7%
Magnetic Resonance Imaging
7%
Arabinoside
7%
Disease
7%
Cytarabine
7%
Patient Characteristics
7%
Neuroscience
Hematopoietic Stem Cell
100%
Relapsing Remitting Multiple Sclerosis
75%
Multiple Sclerosis
56%
Anti-Thymocyte Globulin
37%
Cyclophosphamide
31%
Immunosuppression
25%
Cytarabine
6%
Magnetic Resonance Imaging
6%
Carmustine
6%
Melphalan
6%
Etoposide
6%
Arabinoside
6%
